Status:
COMPLETED
Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the maximum tolerated dose and recommended phase 2 dose of PF-03814735 administered orally as single agent in patients with advanced solid tumors.
Eligibility Criteria
Inclusion
- Metastatic solid tumor resistant to standard therapy or for which no standard therapy is available
- Adequate bone marrow, liver and kidney function
Exclusion
- Brain metastases that are symptomatic and/or require treatment with steroids and/or anticonvulsants, or brain metastases that have been treated within 3 months prior to study start
- Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the previous 6 months
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00424632
Start Date
November 1 2006
End Date
June 1 2009
Last Update
June 25 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Nashville, Tennessee, United States, 37203
2
Pfizer Investigational Site
Leuven, Belgium, 3000